We could not find any results for:
Make sure your spelling is correct or try broadening your search.
– New Commitment by Great Point Partners Brings Proceeds of Transactions to $87 Million – – Current OvaScience Shareholders to Benefit from Improved Exchange Ratio – OvaScienceSM...
OvaScienceSM (Nasdaq:OVAS), a company focused on developing novel treatments for women and couples struggling with infertility, today reported financial results for the second quarter ended...
– Transaction to Advance Millendo’s Compelling Pipeline of Late-Stage Programs for Orphan Endocrine Diseases Including Prader-Willi Syndrome – – Companies to Host Conference Call to...
OvaScienceSM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial results for the first...
– Initial Data from First 20 Patients in Phase 1 Clinical Trial of OvaPrime Indicates Safety and Tolerability; Conducting Additional Preclinical Studies to Optimize Proposed Phase 1b/2a...
OvaScienceSM, Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today...
OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced...
OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced...
– Reporting Safety Data from First 20 Patients in Phase 1 Study of the OvaPrimeSM Treatment; Advancing OvaPrime into Phase 1b/2a Multi-Center Trial – – James Lillie, Ph.D., Joining as...
Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against OvaScience, Inc. PR Newswire NEW YORK, Nov. 28, 2017 NEW YORK, Nov. 28, 2017 /PRNewswire/ -- Bernstein Liebhard LLP...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions